© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Biomarker-Driven Lung Cancer
Adagrasib Demonstrates Significant Disease Control in KRAS G12C+ Non-Small Cell Lung Cancer
October 26, 2020
Adagrasib demonstrated promising antitumor activity as monotherapy in patients with previously treated KRAS G12C–mutant non–small cell lung cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.
Lack of Targeted Therapies for NRG1 Fusion-Positive Advanced Solid Tumors Comes to Attention
October 23, 2020
Driver alterations in neuregulin 1 fusions have recently come to light as a new target in patients with advanced or metastatic solid tumors. Multiple factors contribute to poor outcomes in this patients population with limited option for resolution.
Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung Cancer
October 14, 2020
Vivek Subbiah, MD, discusses how the data from selpercatinib have generated excitement for precision medicine in the treatment landscape for patients with RET-driven lung cancer.
CodeBreaK Update Shows Durable Antitumor Activity With Sotorasib In KRAS-Mutant NSCLC
October 06, 2020
Topline results from the phase 2 CodeBreaK 100 clinical trial were consistent with phase 1 data, withthe KRAS inhibitor sotorasib having achieved a satisfactory objective response rate when administered as treatment of patients with KRAS G12C–mutant non–small cell lung cancer, who had failed a median of 2 prior lines of anti-cancer therapies, which could include immunotherapy and/or chemotherapy.
Selpercatinib Induces Infrequent Hypersensitivity in RET Fusion-Positive NSCLC, Analysis Shows
October 06, 2020
Selpercatinib-related hypersensitivity reactions occurred infrequently in patients with RET fusion-positive non–small cell lung cancer, with more cases reported in patients previously treated with an immune checkpoint inhibitor, but reactions were deemed manageable with recommended guidance and supportive care.
Entrectinib Improves Patient-Reported Outcomes in ROS-1- and TRK Fusion-Positive NSCLC
October 02, 2020
In an interview with Targeted Oncology, Anthony P. Conley, MD, discussed findings from an analysis of the efficacy and safety of entrectinib in patients with non-small cell lung cancer harboring a ROS1 or TRK fusion.
Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung Cancer
September 21, 2020
In patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.
Responses Observed With Poziotinib in HER2-Positive Non-Small Cell Lung Cancer
July 28, 2020
"We believe that poziotinib is a significant advancement for patients with this deadly disease in an area of high unmet medical need."
Pyrotinib Induces Antitumor Activity in HER2-Positive Non-Small Cell Lung Cancer
July 14, 2020
In a single-arm phase 2 clinical trial, pyrotinib had promising antitumor activity as treatment of patients with HER2-positive non–small cell lung cancer.
Adherence to NCCN Guidelines for Biomarker Testing Shows Decreased Risk of Mortality for Non-Squamous aNSCLC
June 12, 2020
The NCCN guidelines recommend biomarker testing as a part of the pathologic evaluation for patients with non-squamous advanced NSCLC and NCC set out to determine how these guidelines decrease the incidence of mortality.